Previous 10 | Next 10 |
Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC; IND filing planned in Q2 2024 Oral presentation demonstrating preclinical efficacy and tolerability data for Selective CBP and Selec...
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will participate in Cowen...
2024-02-16 05:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States NanoString Technologies Inc. (NSTG) rose 164.5% to $0.1407 on volume of 378,097,862 shares U Power Limited (UCAR) rose 55.6% to $0.102517 on volume of 264,170,127 shares Palantir Technologies Inc. Class A (PLTR) rose 5.8% to $24.965 o...
2024-02-08 07:41:07 ET More on Foghorn Therapeutics Seeking Alpha’s Quant Rating on Foghorn Therapeutics Historical earnings data for Foghorn Therapeutics Financial information for Foghorn Therapeutics Read the full article on Seeking Alpha For...
CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Lilly has selected FHD-909, ...
- FHD-286 combination study in AML continues to progress in the clinic with data anticipated in the second half of 2024; preclinical combination data with FHD-286 and tyrosine kinase inhibitors (TKIs) in EGFR/KRAS resistance anticipated by the second quarter of 2024 - BRM selective inhibitor ...
2024-01-03 16:34:46 ET Gainers: iHeartMedia ( IHRT ) +10% . Arcutis Biotherapeutics ( ARQT ) +8% . Cipher Mining ( CIFR ) +7% . Pacira BioSciences ( PCRX ) +6% . Argo Blockchain ( ARBK ) +6% . Losers: Cal-Main...
2024-01-03 16:17:10 ET More on Foghorn Therapeutics Seeking Alpha’s Quant Rating on Foghorn Therapeutics Historical earnings data for Foghorn Therapeutics Financial information for Foghorn Therapeutics For further details see: Foghorn Therapeutics ...
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Chief Financial Officer, All...
News, Short Squeeze, Breakout and More Instantly...
Foghorn Therapeutics Inc. Company Name:
FHTX Stock Symbol:
NASDAQ Market:
Foghorn Therapeutics Inc. Website:
2024-07-18 00:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-06 14:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the Jeffe...